![](https://education.nccn.org/sites/default/files/styles/course_image/public/Case-Manager-Medical-Director-Web-ad-250x170.jpg?itok=DPLB7GFx)
2017 NCCN Case Manager and Medical Director Program: Updates in the Diagnosis and Treatment of B-cell Non-Hodgkin’s Lymphoma
Join Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, as he presents Updates in the Diagnosis and Treatment of B-cell Non-Hodgkin’s Lymphoma as part of the NCCN 2017 Oncology Case Manager and Medical Director Program Webinar Series.
A better understanding of the underlying pathogenesis, identification of new targets, and the development of novel targeted therapies have significantly improved the diagnosis and management of B-cell NHLs. These recent advances underscore the importance of individualizing therapy based on the subtype, natural history of disease, and patient-related factors such as age, performance status, and the presence of comorbidities. Identification of patients at higher risk for developing treatment-related side effects, careful monitoring for any signs and symptoms immediately after initiation of treatment, and implementation of appropriate supportive care interventions are critical to improve clinical outcomes and quality of life.
Target Audience
This program is designed to meet the educational needs of case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.
Learning Objectives
Following this activity, participants should be able to:
- Identify the challenges involved in the diagnosis and management of patients with B-cell NHLs.
- Summarize the recommendations outlined in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) B-Cell Lymphoma for the management of various subtypes of B-cell NHL.
- Review the treatment-related toxicities and develop an effective supportive care plan to monitor and manage potential side effects in patients with B-cell NHLs.
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses the following relevant financial relationships:
Andrew D. Zelenetz, MD, PhD
Adaptive Biotechnologies: Consulting Fees, Honoraria
Amgen Inc.: Consulting Fees, Honoraria
BeiGene: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria
Genentech, Inc.: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria; Grant/Research Support
MEI Pharma Inc.: Grant/Research Support
NanoString® Technologies, Inc.: Consulting Fees, Honoraria
Portola Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fees, Honoraria
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Dwyer, MS; Hema Sundar, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category I credits for completing this activity.
Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.25 contact hours.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. This course is approved for 1.25 CE contact hours. Activity Code: I00028892; Approval #: 170003898
Pharmacists
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: 0836-0000-17-108-L01-P
Available Credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 CCM clock hours
- 1.25 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing